Boston Scientific Co. (NYSE:BSX) Shares Bought by Homestead Advisers Corp

Homestead Advisers Corp grew its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 3.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,179,526 shares of the medical equipment provider's stock after purchasing an additional 43,700 shares during the period. Boston Scientific makes up about 2.5% of Homestead Advisers Corp's investment portfolio, making the stock its 8th largest position. Homestead Advisers Corp owned approximately 0.08% of Boston Scientific worth $105,355,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. NEOS Investment Management LLC increased its stake in Boston Scientific by 16.4% during the 4th quarter. NEOS Investment Management LLC now owns 108,757 shares of the medical equipment provider's stock worth $9,714,000 after buying an additional 15,325 shares during the period. UniSuper Management Pty Ltd increased its position in shares of Boston Scientific by 129.4% during the fourth quarter. UniSuper Management Pty Ltd now owns 975,961 shares of the medical equipment provider's stock worth $87,173,000 after acquiring an additional 550,439 shares during the last quarter. Sava Infond d.o.o. acquired a new position in shares of Boston Scientific in the fourth quarter worth about $4,404,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Boston Scientific by 9.8% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,335,854 shares of the medical equipment provider's stock valued at $211,839,000 after purchasing an additional 207,907 shares during the last quarter. Finally, Penobscot Investment Management Company Inc. boosted its holdings in Boston Scientific by 70.5% in the fourth quarter. Penobscot Investment Management Company Inc. now owns 28,355 shares of the medical equipment provider's stock valued at $2,533,000 after purchasing an additional 11,725 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Boston Scientific

In other news, CFO Daniel J. Brennan sold 67,333 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the sale, the chief financial officer now owns 225,808 shares in the company, valued at $23,764,033.92. This represents a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the transaction, the executive vice president now owns 28,454 shares in the company, valued at $2,966,329.50. This represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 137,302 shares of company stock worth $14,319,269 in the last quarter. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Truist Financial upped their target price on Boston Scientific from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, December 18th. Needham & Company LLC reaffirmed a "hold" rating on shares of Boston Scientific in a report on Monday, March 3rd. Piper Sandler upped their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. UBS Group raised their price objective on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Finally, Argus set a $130.00 target price on shares of Boston Scientific in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $108.91.

Boston Scientific Price Performance

BSX stock traded down $1.51 on Friday, hitting $99.29. 7,402,670 shares of the company's stock traded hands, compared to its average volume of 6,051,507. The stock has a market cap of $146.86 billion, a price-to-earnings ratio of 79.43, a P/E/G ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a fifty day moving average of $102.16 and a 200-day moving average of $93.04.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.